Evidence map›Paper›PMID 37692739›Full record

ArticleCureus2023

A Case of Prolonged Fever in a Patient Infected With COVID-19 on Ofatumumab.

Yasin Uddin, Hector Ramirez, Monish A Sheth

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yasin UddinInternal Medicine, Baylor Scott & White Medical Center, Temple, USA.
Hector RamirezInfectious Diseases, Baylor Scott & White Medical Center, Temple, USA.
Monish A ShethInternal Medicine, Baylor Scott & White Medical Center, Temple, USA.
Baylor Scott & White Medical Center - Temple · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We discuss a case of a 53-year-old woman with multiple sclerosis on monthly ofatumumab injections, who was infected with SARS-CoV-2 with persistent fevers for seven weeks. She was hospitalized for fever with diagnostic workup being unremarkable with negative SARS-CoV-2 IgM and undetectable nucleocapsid IgG antibodies four weeks out from the initial infection, indicating she may not have mounted an appropriate immune response to the infection. Patients on immunosuppression therapy may have a prolonged course of disease given that medications such as ofatumumab can take up to 24 weeks of B-cell recovery post-treatment discontinuation and a longer road to recovery.

Indexed as

anti-cd20 monoclonal antibodiescoronavirus disease 2019 (covid-19)high feverimmunocompromised patientkesimptaofatumumabpaxlovidrelapsing-remitting multiple sclerosis (rrms)sars-cov-2sars-cov-2 infection

Identifiers

PMID37692739
PMCPMC10492571
OpenAlexW4385738017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.